Understanding Idiopathic Interstitial Pneumonia: A Gene-Based Review of Stressed Lungs

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Van Moorsel, Coline H M ^a,b   Hoffman, Thijs W ^a   Van Batenburg, Aernoud A ^a   Klay, Dymph ^a   Van Der Vis, Joanne J ^a   Grutters, Jan C ^a,b  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABCA3 PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 17; INTERLEUKIN 1BETA; LUNG SURFACTANT; MUCIN 5B; PROTEIN; PROTEIN P21; PROTEIN P53; SURFACTANT PROTEIN C; TELOMERASE REVERSE TRANSCRIPTASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; MUC5B PROTEIN, HUMAN;

ALLELE; BACTERIAL LOAD; CAUCASIAN; CELL AGING; CLARA CELL; EMPHYSEMA; ENDOPLASMIC RETICULUM STRESS; ENDOSOME; ENZYME ACTIVITY; ETHNIC DIFFERENCE; FAMILIAL DISEASE; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOINSUFFICIENCY; HISPANIC; HUMAN; IMMUNE DYSREGULATION; IMMUNOCOMPETENT CELL; INTERSTITIAL PNEUMONIA; LAMELLAR BODY; LIPID COMPOSITION; LIPID TRANSPORT; LUNG ALVEOLUS EPITHELIUM CELL; LUNG ALVEOLUS SURFACE TENSION; LUNG FIBROSIS; MACROPHAGE; MECHANICAL STRESS; NONHUMAN; OCULAR ALBINISM; PATHOGENESIS; PENETRANCE; PREMATURE AGING; PROMOTER REGION; REVIEW; TELOMERE HOMEOSTASIS; TELOMERE LENGTH; UNFOLDED PROTEIN RESPONSE; VARIABLE NUMBER OF TANDEM REPEAT; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; INTERSTITIAL LUNG DISEASE; LUNG; METABOLISM; MUTATION; PATHOPHYSIOLOGY; TELOMERE;

GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IDIOPATHIC INTERSTITIAL PNEUMONIAS; LUNG; LUNG DISEASES, INTERSTITIAL; MUCIN-5B; MUTATION; STRESS, MECHANICAL; TELOMERE;

EID: 84946017657     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/304186     Document Type: Review

References (170)

1. G. Raghu, H. R. Collard, J. J. Egan et al., "An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management," American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 6, pp. 788-824, 2011.
2. T. M. Maher, A. U. Wells, and G. J. Laurent, "Idiopathic pulmonary fibrosis:multiple causes andmultiple mechanisms?" European Respiratory Journal, vol. 30, no. 5, pp. 835-839, 2007.
3. M. P. Steele, M. C. Speer, J. E. Loyd et al., "Clinical and pathologic features of familial interstitial pneumonia," American Journal of Respiratory and Critical Care Medicine, vol. 172, no. 9, pp. 1146-1152, 2005.
4. W. D. Travis, U. Costabel, D.M. Hansell et al., "Anofficial American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias," American Journal of Respiratory and Critical Care Medicine, vol. 188, no. 6, pp. 733-748, 2013.
5. J. J. Swigris, A. L. Olson, T. J. Huie et al., "Ethnic and racial differences in the presence of idiopathic pulmonary fibrosis at death," Respiratory Medicine, vol. 106, no. 4, pp. 588-593, 2012.
6. L.M. Young, R. Hopkins, and M. L. Wilsher, "Lower occurrence of idiopathic pulmonary fibrosis in maori and pacific islanders," Respirology, vol. 11, no. 4, pp. 467-470, 2006.
7. P. P. Bonanni, J. W. Frymoyer, and R. F. Jacox, "A family study of idiopathic pulmonary fibrosis. A possible dysproteinemic and genetically determined disease," The American Journal of Medicine, vol. 39, no. 3, pp. 411-421, 1965.
8. P. Swaye, H. S. Van Ordstrand, L. J. McCormack, and S. E. Wolpaw, "Familial hamman-rich syndrome. Report of eight cases," Chest, vol. 55, no. 1, pp. 7-12, 1969.
9. M. Schou, A. Amdisen, S. Eskjaer Jensen, and T. Olsen, "Occurrence of goitre during lithium treatment," The British Medical Journal, vol. 3, no. 5620, pp. 710-713, 1968.
10. C. H.M. van Moorsel, M. F. M. van Oosterhout, N. P. Barlo et al., "Surfactant protein Cmutations are the basis of a significant portion of adult familial pulmonary fibrosis in a dutch cohort," American Journal of Respiratory and Critical Care Medicine, vol. 182, no. 11, pp. 1419-1425, 2010.
11. J. E. Loyd, "Pulmonary fibrosis in families," American Journal of Respiratory Cell and Molecular Biology, vol. 29, no. 3, supplement, pp. S47-S50, 2003.
12. C. García-Sancho, I. Buendía-Roldán, M. R. Fernández-Plata et al., "Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis," Respiratory Medicine, vol. 105, no. 12, pp. 1902-1907, 2011.
13. M. B. Scholand, H. Coon, R. Wolff, and L. Cannon-Albright, "Use of a genealogical database demonstrates heritability of pulmonary fibrosis," Lung, vol. 191, no. 5, pp. 475-481, 2013.
14. L. M. Nogee, A. E. Dunbar, S. E. Wert, F. Askin, A. Hamvas, and J. A. Whitsett, "A mutation in the surfactant protein C gene associated with familial interstitial lung disease," The New England Journal of Medicine, vol. 344, no. 8, pp. 573-579, 2001.
15. S. Ono, T. Tanaka, M. Ishida et al., "Surfactant protein C G100S mutation causes familial pulmonary fibrosis in Japanese kindred," European Respiratory Journal, vol. 38, no. 4, pp. 861-869, 2011.
16. A. Q. Thomas, K. Lane, J. Phillips III et al., "Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred," American Journal of Respiratory and Critical Care Medicine, vol. 165, no. 9, pp. 1322-1328, 2002.
17. W. E. Lawson, S. W. Grant, V. Ambrosini et al., "Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF," Thorax, vol. 59, no. 11, pp. 977-980, 2004.
18. P. Markart, C. Ruppert, M. Wygrecka et al., "Surfactant protein C mutations in sporadic forms of idiopathic interstitial pneumonias," European Respiratory Journal, vol. 29, no. 1, pp. 134-137, 2007.
19. A. Hamvas, L. M. Nogee, F. V. White et al., "Progressive lung disease and surfactant dysfunction with a deletion in surfactant protein C gene," American Journal of Respiratory Cell and Molecular Biology, vol. 30, no. 6, pp. 771-776, 2004.
20. S. Mulugeta, J. M. Gray, K. L. Notarfrancesco et al., "Identification of LBM180, a lamellar body limiting membrane protein of alveolar type II cells, as the ABC transporter protein ABCA3," The Journal of Biological Chemistry, vol. 277, no. 25, pp. 22147-22155, 2002.
21. M. F. Beers and S. Mulugeta, "Surfactant protein C biosynthesis and its emerging role in conformational lung disease," Annual Review of Physiology, vol. 67, pp. 663-696, 2005.
22. J. A. Kropski, W. E. Lawson, L. R. Young, and T. S. Blackwell, "Genetic studies provide clues on the pathogenesis of idiopathic pulmonary fibrosis," Disease Models and Mechanisms, vol. 6, no. 1, pp. 9-17, 2013.
23. W. E. Lawson, P. F. Crossno, V. V. Polosukhin et al., "Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection," American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 294, no. 6, pp. L1119-L1126, 2008.
24. H. Tanjore, D.-S. Cheng, A. L. Degryse et al., "Alveolar epithelial cells undergo epithelial-to-mesenchymal transition in response to endoplasmic reticulum stress," The Journal of Biological Chemistry, vol. 286, no. 35, pp. 30972-30980, 2011.
25. S. Mulugeta, J. A. Maguire, J. L. Newitt, S. J. Russo, A. Kotorashvili, and M. F. Beers, "Misfolded BRICHOS SPC mutant proteins induce apoptosis via caspase-4- and cytochrome c-related mechanisms," The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 293, no. 3, pp. L720-L729, 2007.
26. B. D. Uhal and H. Nguyen, "The witschi hypothesis revisited after 35 years: genetic proof from SP-C BRICHOS domain mutations," The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 305, no. 12, pp. L906-L911, 2013.
27. M. Korfei, C. Ruppert, P. Mahavadi et al., "Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis," American Journal of Respiratory and Critical Care Medicine, vol. 178, no. 8, pp. 838-846, 2008.
28. H. S. Cameron, M. Somaschini, P. Carrera et al., "A common mutation in the surfactant protein C gene associated with lung disease," The Journal of Pediatrics, vol. 146, no. 3, pp. 370-375, 2005.
29. M. F. Beers, A. Hawkins, J. A. Maguire et al., "A nonaggregating surfactant protein C mutant is misdirected to early endosomes and disrupts phospholipid recycling," Traffic, vol. 12, no. 9, pp. 1196-1210, 2011.
30. A. Hawkins, S. H. Guttentag, R. Deterding et al., "A non-BRICHOS SFTPC mutant (SP-CI73T) linked to interstitial lung disease promotes a late block in macroautophagy disrupting cellular proteostasis and mitophagy," American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 308, no. 1, pp. L33-L47, 2015.
31. M. Woischnik, C. Sparr, S. Kern et al., "A non-BRICHOS surfactant protein c mutation disrupts epithelial cell function and intercellular signaling," BMC Cell Biology, vol. 11, article 88, 2010.
32. Y. Wang, P. J. Kuan, C. Xing et al., "Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer," American Journal of Human Genetics, vol. 84, no. 1, pp. 52-59, 2009.
33. J. Madsen, I. Tornøe, O. Nielsen, C. Koch, W. Steinhilber, and U. Holmskov, "Expression and localization of lung surfactant protein A in human tissues," American Journal of Respiratory Cell and Molecular Biology, vol. 29, no. 5, pp. 591-597, 2003.
34. J. Floros, G. Wang, and A. N. Mikerov, "Genetic complexity of the human innate host defense molecules, surfactant protein A1 (SP-A1) and SP-A2-impact on function," Critical Reviews in Eukaryotic Gene Expression, vol. 19, no. 2, pp. 125-137, 2009.
35. M. Maitra, Y. Wang, R. D. Gerard, C. R. Mendelson, and C. K. Garcia, "Surfactant protein A2 mutations associated with pulmonary fibrosis lead to protein instability and endoplasmic reticulum stress," The Journal of Biological Chemistry, vol. 285, no. 29, pp. 22103-22113, 2010.
36. B. Zhu, C. H. Ferry, L. K. Markell et al., "The nuclear receptor peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) promotes oncogene-induced cellular senescence through repression of endoplasmic reticulum stress," Journal of Biological Chemistry, vol. 289, no. 29, pp. 20102-20119, 2014.
37. S.A. Yousemand M. B. Beasley, "Bronchioloalveolar carcinoma: a review of current concepts and evolving issues," Archives of Pathology and Laboratory Medicine, vol. 131, no. 7, pp. 1027-1032, 2007.
38. S. Shulenin, L. M. Nogee, T. Annilo, S. E. Wert, J. A. Whitsett, and M. Dean, "ABCA3 gene mutations in newborns with fatal surfactant deficiency," The New England Journal of Medicine, vol. 350, no. 13, pp. 1296-1303, 2004.
39. F. Flamein, L. Riffault, C. Muselet-Charlier et al., "Molecular and cellular characteristics of ABCA3 mutations associated with diffuse parenchymal lung diseases in children," Human Molecular Genetics, vol. 21, no. 4, pp. 765-775, 2012.
40. G. H. Deutsch, L. R. Young, R. R. Deterding et al., "Diffuse lung disease in young children: application of a novel classification scheme," American Journal of Respiratory and Critical Care Medicine, vol. 176, no. 11, pp. 1120-1128, 2007.
41. 3 mutants associated with respiratory distress syndrome," Journal of Biological Chemistry, vol. 281, no. 14, pp. 9791-9800, 2006.
42. Y. Matsumura, N. Ban, K. Ueda, and N. Inagaki, "Characterization and classification of ATP-binding cassette transporter ABCA3 mutants in fatal surfactant deficiency," Journal of Biological Chemistry, vol. 281, no. 45, pp. 34503-34514, 2006.
43. Y. Matsumura, N. Ban, and N. Inagaki, "Aberrant catalytic cycle and impaired lipid transport into intracellular vesicles in ABCA3 mutants associated with nonfatal pediatric interstitial lung disease," The American Journal of Physiology: Lung Cellular and Molecular Physiology, vol. 295, no. 4, pp. L698-L707, 2008.
44. N. Weichert, E. Kaltenborn, A. Hector et al., "Some ABCA3 mutations elevate ER stress and initiate apoptosis of lung epithelial cells," Respiratory Research, vol. 12, article 4, 2011.
45. I. Campo, M. Zorzetto, F. Mariani et al., "A large kindred of pulmonary fibrosis associated with a novel ABCA3 gene variant," Respiratory Research, vol. 15, article 43, 2014.
46. R. Epaud, C. Delestrain, M. Louha, S. Simon, P. Fanen, and A. Tazi, "Combined pulmonary fibrosis and emphysema syndrome associated with ABCA3 mutations," European Respiratory Journal, vol. 43, no. 2, pp. 638-641, 2014.
47. V. Cottin, H. Nunes, P.-Y. Brillet et al., "Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity," European Respiratory Journal, vol. 26, no. 4, pp. 586-593, 2005.
48. M. Brantly, N. A. Avila, V. Shotelersuk, C. Lucero, M. Huizing, and W. A. Gahl, "Pulmonary function and high-resolution CT findings in patients with an inherited form of pulmonary fibrosis, Hermansky-Pudlak syndrome, due to mutations in HPS-1," Chest, vol. 117, no. 1, pp. 129-136, 2000.
49. C. Carmona-Rivera, D. R. Simeonov, N. D. Cardillo, W. A. Gahl, and C. L. Cadilla, "A divalent interaction between HPS1 and HPS4 is required for the formation of the biogenesis of lysosome-related organelle complex-3 (BLOC-3)," Biochimica et Biophysica Acta, vol. 1833, no. 3, pp. 468-478, 2013.
50. S. M. Casalino-Matsuda, M. E. Monzon, A. J. Day, and R. M. Forteza, "Hyaluronan fragments/CD44 mediate oxidative stress-induced MUC5B up-regulation in airway epithelium," The American Journal of Respiratory Cell and Molecular Biology, vol. 40, no. 3, pp. 277-285, 2009.
51. A.-H. Wei and W. Li, "Hermansky-Pudlak syndrome: pigmentary and non-pigmentary defects and their pathogenesis," Pigment Cell and Melanoma Research, vol. 26, no. 2, pp. 176-192, 2013.
52. D. M. Pierson, D. Ionescu, G. Qing et al., "Pulmonary fibrosis in Hermansky-Pudlak syndrome: a case report and review," Respiration, vol. 73, no. 3, pp. 382-395, 2006.
53. K. Furuhashi, N. Enomoto, T. Fujisawa et al., "Hermansky-Pudlak syndrome with nonspecific interstitial pneumonia," Internal Medicine, vol. 53, no. 5, pp. 449-453, 2014.
54. J. J. van der Vis, L. ten Klooster, M. F. M. van Oosterhout, J. C. Grutters, and C. H. M. van Moorsel, "The occurrence of hermansky pudlak syndrome in patients with idiopathic pulmonary fibrosis-a cohort study," Journal of Genetic Syndromes & Gene Therapy, vol. 4, article 141, 2013.
55. M. Y. Armanios, J. J.-L. Chen, J. D. Cogan et al., "Telomerase mutations in families with idiopathic pulmonary fibrosis," The New England Journal of Medicine, vol. 356, no. 13, pp. 1317-1326, 2007.
56. K. D. Tsakiri, J. T. Cronkhite, P. J. Kuan et al., "Adult-onset pulmonary fibrosis caused by mutations in telomerase," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 18, pp. 7552-7557, 2007.
57. M. Armanios, "Telomeres and age-related disease: how telomere biology informs clinical paradigms," The Journal of Clinical Investigation, vol. 123, no. 3, pp. 996-1002, 2013.
58. A. J. Zaug, S. M. Crary, M. J. Fioravanti, K. Campbell, and T. R. Cech, "Many disease-associated variants of hTERT retain high telomerase enzymatic activity," Nucleic Acids Research, vol. 41, no. 19, pp. 8969-8978, 2013.
59. T. Vulliamy, A. Marrone, R. Szydlo, A. Walne, P. J. Mason, and I. Dokal, "Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC," Nature Genetics, vol. 36, no. 5, pp. 447-449, 2004.
60. J. T. Cronkhite, C. Xing, G. Raghu et al., "Telomere shortening in familial and sporadic pulmonary fibrosis," American Journal of Respiratory and Critical Care Medicine, vol. 178, no. 7, pp. 729-737, 2008.
61. J. K. Alder, J. J.-L. Chen, L. Lancaster et al., "Short telomeres are a risk factor for idiopathic pulmonary fibrosis," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 35, pp. 13051-13056, 2008.
62. R. Snetselaar, C. H. van Moorsel, K. M. Kazemier et al., "Telomere length in interstitial lung diseases," Chest, 2015.
63. J. K. Alder, S. E. Stanley, C. L. Wagner, M. Hamilton, V. S. Hanumanthu, and M. Armanios, "Exome sequencing identifies mutant TINF2 in a family with pulmonary fibrosis," Chest, vol. 147, no. 5, pp. 1361-1368, 2015.
64. J. A. Kropski, D. B. Mitchell, C. Markin et al., "A novel dyskerin (DKC1)mutation is associated with familial interstitial pneumonia," Chest, vol. 146, no. 1, pp. e1-e7, 2014.
65. J.D. Cogan, J. A. Kropski, M. Zhao et al., "Rare variants in RTEL1 are associated with familial interstitial pneumonia," American Journal of Respiratory and Critical Care Medicine, vol. 191, no. 6, pp. 646-655, 2015.
66. C. Kannengiesser, R. Borie, C. Menard et al., "Heterozygous RTEL1 mutations are associated with familial pulmonary fibrosis," European Respiratory Journal, vol. 46, no. 2, pp. 474-485, 2015.
67. B. D. Stuart, J. Choi, S. Zaidi et al., "Exome sequencing links mutations in PARNand RTEL1 with familial pulmonary fibrosis and telomere shortening," Nature Genetics, vol. 47, no. 5, pp. 512-517, 2015.
68. C. E. Barkauskas, M. J. Cronce, C. R. Rackley et al., "Type 2 alveolar cells are stem cells in adult lung," The Journal of Clinical Investigation, vol. 123, no. 7, pp. 3025-3036, 2013.
69. D. Warburton, L. Perin, R. Defilippo, S. Bellusci, W. Shi, and B. Driscoll, "Stem/progenitor cells in lung development, injury repair, and regeneration," Proceedings of the American Thoracic Society, vol. 5, no. 6, pp. 703-706, 2008.
70. J.K. Alder, C.E. Barkauskas, N. Limjunyawong et al., "Telomere dysfunction causes alveolar stem cell failure," Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 16, pp. 5099-5104, 2015.
71. M. Plataki, A. V. Koutsopoulos, K. Darivianaki, G. Delides, N. M. Siafakas, and D. Bouros, "Expression of apoptotic and antiapoptotic markers in epithelial cells in idiopathic pulmonary fibrosis," Chest, vol. 127, no. 1, pp. 266-274, 2005.
72. N. M. Korthagen, C. H. M. van Moorsel, N. P. Barlo, K. M. Kazemier, H. J. T. Ruven, and J. C. Grutters, "Association between variations in cell cycle genes and idiopathic pulmonary fibrosis," PLoS ONE, vol. 7, no. 1, Article ID e30442, 2012.
73. J. C. Grutters and R. M. du Bois, "Genetics of fibrosing lung diseases," European Respiratory Journal, vol. 25, no. 5, pp. 915-927, 2005.
74. N. P. Barlo, C. H. M. van Moorsel, N. M. Korthagen et al., "Genetic variability in the IL1RN gene and the balance between interleukin (IL)-1 receptor agonist and IL-1beta in idiopathic pulmonary fibrosis," Clinical and Experimental Immunology, vol. 166, no. 3, pp. 346-351, 2011.
75. R. L. Riha, I. A. Yang, G. C. Rabnott, A. M. Tunnicliffe, K. M. Fong, and P. V. Zimmerman, "Cytokine gene polymorphisms in idiopathic pulmonary fibrosis," Internal Medicine Journal, vol. 34, no. 3, pp. 126-129, 2004.
76. M. Whyte, R. Hubbard, R. Meliconi et al., "Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-α gene polymorphisms," The American Journal of Respiratory and Critical Care Medicine, vol. 162, no. 2, pp. 755-758, 2000.
77. B. Hutyrova, P. Pantelidis, J. Drabek et al., "Interleukin-1 gene cluster polymorphisms in sarcoidosis and idiopathic pulmonary fibrosis," American Journal of Respiratory and Critical Care Medicine, vol. 165, no. 2, pp. 148-151, 2002.
78. N. M. Korthagen, C. H. M. van Moorsel, K. M. Kazemier, H. J. T. Ruven, and J. C. Grutters, "IL1RN genetic variations and risk of IPF: a meta-analysis and mRNA expression study," Immunogenetics, vol. 64, no. 5, pp. 371-377, 2012.
79. P. Gasse, C. Mary, I. Guenon et al., "IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice," The Journal of Clinical Investigation, vol. 117, no. 12, pp. 3786-3799, 2007.
80. I. Aksentijevich, S. L. Masters, P. J. Ferguson et al., "An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist," The New England Journal of Medicine, vol. 360, no. 23, pp. 2426-2437, 2009.
81. E. Arzt, J. Sauer, T. Pollmächer et al., "Glucocorticoids suppress interleukin-1 receptor antagonist synthesis following induction by endotoxin," Endocrinology, vol. 134, no. 2, pp. 672-677, 1994.
82. G. Raghu, K. J. Anstrom, T. E. King Jr., J. A. Lasky, and F. J. Martinez, "Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis," The New England Journal of Medicine, vol. 366, no. 21, pp. 1968-1977, 2012.
83. M. A. Seibold, A. L. Wise, M. C. Speer et al., "A common MUC5B promoter polymorphism and pulmonary fibrosis," The New England Journal of Medicine, vol. 364, no. 16, pp. 1503-1512, 2011.
84. Y. Zhang, I. Noth, J. G. N. Garcia, and N. Kaminski, "A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis," The New England Journal of Medicine, vol. 364, no. 16, pp. 1576-1577, 2011.
85. W. Bodmer and C. Bonilla, "Common and rare variants inmultifactorial susceptibility to common diseases," Nature Genetics, vol. 40, no. 6, pp. 695-701, 2008.
86. A. L. Peljto, M. Selman, D. S. Kim et al., "The MUC5B promoter polymorphism is associated with idiopathic pulmonary fibrosis in a Mexican cohort but is rare among Asian ancestries," Chest, vol. 147, no. 2, pp. 460-464, 2015.
87. Y. Horimasu, S. Ohshimo, F. Bonella et al., "MUC5B promoter polymorphism in Japanese patients with idiopathic pulmonary fibrosis," Respirology, vol. 20, no. 3, pp. 439-444, 2015.
88. M. A. Seibold, R. W. Smith, C. Urbanek et al., "The idiopathic pulmonary fibrosis honeycomb cyst contains a mucocilary pseudostratified epithelium," PLoS ONE, vol. 8, no. 3, Article ID e58658, 2013.
89. Y. Chen, Y. H. Zhao, Y.-P. Di, and R. Wu, "Characterization of human mucin 5B gene expression in airway epithelium and the genomic clone of the amino-terminal and 5′-flanking region," American Journal of Respiratory Cell and Molecular Biology, vol. 25, no. 5, pp. 542-553, 2001.
90. M. C. Rose and J. A. Voynow, "Respiratory tract mucin genes and mucin glycoproteins in health and disease," Physiological Reviews, vol. 86, no. 1, pp. 245-278, 2006.
91. T. Fujisawa, M. M.-J. Chang, S. Velichko et al., "NF-κB mediates IL-1β- and IL-17A-induced MUC5B expression in airway epithelial cells," The American Journal of Respiratory Cell and Molecular Biology, vol. 45, no. 2, pp. 246-252, 2011.
92. G. P. Cosgrove, S. D. Groshong, A. L. Peljto et al., "The MUC5B promoter polymorphism is associated with a less severe pathological formof familial interstitial pneumonia (FIP)," American Journal of Respiratory and Critical Care Medicine, vol. 185, Article ID A6865, 2012.
93. M. G. Roy, A. Livraghi-Butrico, A. A. Fletcher et al., "Muc5b is required for airway defence," Nature, vol. 505, no. 7483, pp. 412-416, 2014.
94. P. L. Molyneaux, M. J. Cox, S. A. G. Willis-Owen et al., "The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis," American Journal of Respiratory and Critical Care Medicine, vol. 190, no. 8, pp. 906-913, 2014.
95. A. L. Peljto, Y. Zhang, T. E. Fingerlin et al., "Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis," Journal of the American Medical Association, vol. 309, no. 21, pp. 2232-2239, 2013.
96. C. J. Stock, H. Sato, C. Fonseca et al., "Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis," Thorax, vol. 68, no. 5, pp. 436-441, 2013.
97. T. Mushiroda, S. Wattanapokayakit, A. Takahashi et al., "A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis," Journal of Medical Genetics, vol. 45, no. 10, pp. 654-656, 2008.
98. T. E. Fingerlin, E. Murphy, W. Zhang et al., "Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis," Nature Genetics, vol. 45, no. 6, pp. 613-620, 2013.
99. H. Corvol, C.A. Hodges, M. L. Drumm, and L. Guillot, "Moving beyond genetics: is FAM13A a major biological contributor in lung physiology and chronic lung diseases?" Journal of Medical Genetics, vol. 51, no. 10, pp. 646-649, 2014.
100. I. Noth, Y. Zhang, S.-F. Ma et al., "Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study," The Lancet Respiratory Medicine, vol. 1, no. 4, pp. 309-317, 2013.
101. D. E. Reich, M. Cargili, S. Boik et al., "Linkage disequilibrium in the human genome," Nature, vol. 411, no. 6834, pp. 199-204, 2001.
102. W. Y. S. Wang, B. J. Barratt, D. G. Clayton, and J. A. Todd, "Genome-wide association studies: theoretical and practical concerns," Nature Reviews Genetics, vol. 6, no. 2, pp. 109-118, 2005.
103. G. M. Hunninghake, H. Hatabu, Y. Okajima et al., "MUC5B promoter polymorphism and interstitial lung abnormalities," The New England Journal of Medicine, vol. 368, no. 23, pp. 2192-2200, 2013.
104. K. O. Leslie, "Idiopathic pulmonary fibrosis may be a disease of recurrent, tractional injury to the periphery of the aging lung: a unifying hypothesis regarding etiology and pathogenesis," Archives of Pathology and Laboratory Medicine, vol. 136, no. 6, pp. 591-600, 2012.
105. A. Carloni, V. Poletti, L. Fermo, N. Bellomo, and M. Chilosi, "Heterogeneous distribution of mechanical stress in human lung: a mathematical approach to evaluate abnormal remodeling in IPF," Journal of Theoretical Biology, vol. 332, pp. 136-140, 2013.
106. D. Shier, J. Butler, and R. Lewis, "Respiratory system," in Hole's Human Anatomy and Physiology, chapter 19, pp. 752-790, McGraw-Hill, 11th edition, 2007.
107. J. A. Whitsett, S. E. Wert, and T. E. Weaver, "Alveolar surfactant homeostasis and the pathogenesis of pulmonary disease," Annual Review of Medicine, vol. 61, pp. 105-119, 2010.
108. R. Zarbock, M. Woischnik, C. Sparr et al., "The surfactant proteinCmutation A116D alters cellular processing, stress tolerance, surfactant lipid composition, and immune cell activation," BMC Pulmonary Medicine, vol. 12, article 15, 2012.
109. J. A. Maguire, S. Mulugeta, and M. F. Beers, "Endoplasmic reticulum stress induced by surfactant protein C BRICHOS mutants promotes proinflammatory signaling by epithelial cells," American Journal of Respiratory Cell and Molecular Biology, vol. 44, no. 3, pp. 404-414, 2011.
110. S. Mulugeta, V. Nguyen, S. J. Russo, M. Muniswamy, and M. F. Beers, "A surfactant protein C precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress, proteasome dysfunction, and caspase 3 activation," American Journal of Respiratory Cell and Molecular Biology, vol. 32, no. 6, pp. 521-530, 2005.
111. J. A. Maguire, S. Mulugeta, and M. F. Beers, "Multiple ways to die: delineation of the unfolded protein response and apoptosis induced by surfactant protein C BRICHOS mutants," International Journal of Biochemistry and Cell Biology, vol. 44, no. 1, pp. 101-112, 2012.
112. T. Thurm, E. Kaltenborn, S. Kern, M. Griese, and R. Zarbock, "SFTPC mutations cause SP-C degradation and aggregate formation without increasing ER stress," European Journal of Clinical Investigation, vol. 43, no. 8, pp. 791-800, 2013.
113. K. R. Khubchandani, K. L. Goss, J. F. Engelhardt, and J. M. Snyder, "In situ hybridization of SP-A mRNA in adult human conducting airways," Pediatric Pathology and Molecular Medicine, vol. 20, no. 5, pp. 349-366, 2001.
114. H. Saitoh, H. Okayama, S. Shimura, T. Fushimi, T. Masuda, and K. Shirato, "Surfactant protein A2 gene expression by human airway submucosal gland cells," American Journal of Respiratory Cell and Molecular Biology, vol. 19, no. 2, pp. 202-209, 1998.
115. M. J. Tino and J. R. Wright, "Interactions of surfactant protein A with epithelial cells and phagocytes," Biochimica et Biophysica Acta-Molecular Basis of Disease, vol. 1408, no. 2-3, pp. 241-263, 1998.
116. C. J. Wong, J. Akiyama, L. Allen, and S. Hawgood, "Localization and developmental expression of surfactant proteins D and A in the respiratory tract of the mouse," Pediatric Research, vol. 39, no. 6, pp. 930-937, 1996.
117. A.M. Pastva, J. R. Wright, and K. L. Williams, "Immunomodulatory roles of surfactant proteins A and D: implications in lung disease," Proceedings of the American Thoracic Society, vol. 4, no. 3, pp. 252-257, 2007.
118. Y. Wang, P. J. Kuan, C. Xing et al., "Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer," The American Journal of Human Genetics, vol. 84, no. 1, pp. 52-59, 2009.
119. Y. Song, G. Fang, H. Shen et al., "Human surfactant protein A2 gene mutations impair dimmer/trimer assembly leading to deficiency in protein sialylation and secretion," PLoS ONE, vol. 7, no. 10, Article ID e46559, 2012.
120. G. Yamano, H. Funahashi, O. Kawanami et al., "ABCA3 is a lamellar body membrane protein in human lung alveolar type II cells," FEBS Letters, vol. 508, no. 2, pp. 221-225, 2001.
121. E. Bruder, J. Hofmeister, C. Aslanidis et al., "Ultrastructural and molecular analysis in fatal neonatal interstitial pneumonia caused by a novel ABCA3mutation," Modern Pathology, vol. 20, no. 10, pp. 1009-1018, 2007.
122. T. H. Garmany, M. A. Moxley, F. V. White et al., "Surfactant composition and function in patients with ABCA3 mutations," Pediatric Research, vol. 59, no. 6, pp. 801-805, 2006.
123. B. Driscoll, S. Buckley, K. C. Bui, K. D. Anderson, and D. Warburton, "Telomerase in alveolar epithelial development and repair," The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 279, no. 6, pp. L1191-L1198, 2000.
124. T. Liu, M. Ullenbruch, Y. Y. Choi et al., "Telomerase and telomere length in pulmonary fibrosis," American Journal of Respiratory Cell and Molecular Biology, vol. 49, no. 2, pp. 260-268, 2013.
125. Y. Nozaki, T. Liu, K. Hatano, M. Gharaee-Kermani, and S. H. Phan, "Induction of telomerase activity in fibroblasts from bleomycin-injured lungs," American Journal of Respiratory Cell and Molecular Biology, vol. 23, no. 4, pp. 460-465, 2000.
126. Z. G. Fridlender, P. Y. Cohen, O. Golan, N. Arish, S. Wallach-Dayan, and R. Breuer, "Telomerase activity in bleomycininduced epithelial cell apoptosis and lung fibrosis," European Respiratory Journal, vol. 30, no. 2, pp. 205-213, 2007.
127. C.W. Greider and E. H. Blackburn, "Identification of a specific telomere terminal transferase activity in tetrahymena extracts," Cell, vol. 43, no. 2, part 1, pp. 405-413, 1985.
128. J.-L. Chen and C. W. Greider, "Telomerase RNA structure and function: implications for dyskeratosis congenita," Trends in Biochemical Sciences, vol. 29, no. 4, pp. 183-192, 2004.
129. C. W. Greider and E. H. Blackburn, "The telomere terminal transferase of tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity," Cell, vol. 51, no. 6, pp. 887-898, 1987.
130. C.W. Greider and E. H. Blackburn, "Atelomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis," Nature, vol. 337, no. 6205, pp. 331-337, 1989.
131. A. Diaz de Leon, J. T. Cronkhite, A.-L. A. Katzenstein et al., "Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations," PLoS ONE, vol. 5, no. 5, Article ID e10680, 2010.
132. J. M. Gansner, I. O. Rosas, and B. L. Ebert, "Pulmonary fibrosis, bone marrow failure, and telomerase mutation," The New England Journal of Medicine, vol. 366, no. 16, pp. 1551-1553, 2012.
133. E. M. Parry, J. K. Alder, X. Qi, J. J.-L. Chen, and M. Armanios, "Syndrome complex of bone marrow failure and pulmonary fibrosis predicts germline defects in telomerase," Blood, vol. 117, no. 21, pp. 5607-5611, 2011.
134. D.C. Chambers, B. E. Clarke, J. McGaughran, and C.K. Garcia, "Lung fibrosis, premature graying, andmacrocytosis," American Journal of Respiratory and Critical Care Medicine, vol. 186, no. 5, pp. e8-e9, 2012.
135. R. T. Calado, J. A. Regal, D. E. Kleiner et al., "A spectrum of severe familial liver disorders associate with telomerase mutations," PLoS ONE, vol. 4, no. 11, Article ID e7926, 2009.
136. M. Armanios, J.-L. Chen, Y.-P. C. Chang et al., "Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 44, pp. 15960-15964, 2005.
137. H.-Y. Du, R. Idol, S. Robledo et al., "Telomerase reverse transcriptase haploinsufficiency and telomere length in individuals with 5p-syndrome," Aging Cell, vol. 6, no. 5, pp. 689-697, 2007.
138. C. K. Garcia, W. E. Wright, and J. W. Shay, "Human diseases of telomerase dysfunction: insights into tissue aging," Nucleic Acids Research, vol. 35, no. 22, pp. 7406-7416, 2007.
139. J. K. Alder, N. Guo, F. Kembou et al., "Telomere length is a determinant of emphysema susceptibility," American Journal of Respiratory and Critical Care Medicine, vol. 184, no. 8, pp. 904-912, 2011.
140. S.-R. Jackson, J. Lee, R. Reddy et al., "Partial pneumonectomy of telomerase null mice carrying shortened telomeres initiates cell growth arrest resulting in a limited compensatory growth response," The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 300, no. 6, pp. L898-L909, 2011.
141. H. Ly, M. Schertzer, W. Jastaniah et al., "Identification and functional characterization of 2 variant alleles of the telomerase RNA template gene (TERC) in a patient with dyskeratosis congenita," Blood, vol. 106, no. 4, pp. 1246-1252, 2005.
142. A. Marrone, P. Sokhal, A. Walne et al., "Functional characterization of novel telomerase RNA (TERC) mutations in patients with diverse clinical and pathological presentations," Haematologica, vol. 92, no. 8, pp. 1013-1020, 2007.
143. F. Goldman, R. Bouarich, S. Kulkarni et al., "The effect of TERC haploinsufficiency on the inheritance of telomere length," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 47, pp. 17119-17124, 2005.
144. T. Vulliamy, A. Marrone, F. Goldman et al., "The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita," Nature, vol. 413, no. 6854, pp. 432-435, 2001.
145. N. S. Heiss, S. W. Knight, T. J. Vulliamy et al., "X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions," Nature Genetics, vol. 19, no. 1, pp. 32-38, 1998.
146. J. K. Alder, E. M. Parry, S. Yegnasubramanian et al., "Telomere phenotypes in females with heterozygous mutations in the dyskeratosis congenita 1 (DKC1) gene," Human Mutation, vol. 34, no. 11, pp. 1481-1485, 2013.
147. W. F. Safa, G. G. Lestringant, and P. M. Frossard, "X-linked dyskeratosis congenita: restrictive pulmonary disease and a novel mutation," Thorax, vol. 56, no. 11, pp. 891-894, 2001.
148. S. Hisata, H. Sakaguchi, H. Kanegane et al., "A novel missense mutation of DKC1 in dyskeratosis congenita with pulmonary fibrosis," Sarcoidosis Vasculitis and Diffuse Lung Diseases, vol. 30, no. 3, pp. 221-225, 2013.
149. L. A. Dvorak, R. Vassallo, S. Kirmani et al., "Pulmonary fibrosis in dyskeratosis congenita: report of 2 cases," Human Pathology, vol. 46, no. 1, pp. 147-152, 2014.
150. S.-H. Kim, P. Kaminker, and J. Campisi, "TIN2, a new regulator of telomere length in human cells," Nature Genetics, vol. 23, no. 4, pp. 405-412, 1999.
151. W. Palm and T. de Lange, "How shelterin protects mammalian telomeres," Annual Review of Genetics, vol. 42, pp. 301-334, 2008.
152. A. Fukuhara, Y. Tanino, T. Ishii et al., "Pulmonary fibrosis in dyskeratosis congenita with TINF2 gene mutation," European Respiratory Journal, vol. 42, no. 6, pp. 1757-1759, 2013.
153. A. J. Walne, T. Vulliamy, R. Beswick, M. Kirwan, and I. Dokal, "TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrowfailure syndromes," Blood, vol. 112, no.9, pp. 3594-3600, 2008.
154. H. Ding, M. Schertzer, X. Wu et al., "Regulation of murine telomere length by Rtel: an essential gene encoding a helicaselike protein," Cell, vol. 117, no. 7, pp. 873-886, 2004.
155. Z. Du, D. Zhao, Y. Zhao, S. Wang, Y. Gao, and N. Li, "Identification and characterization of bovine regulator of telomere length elongation helicase gene (RTEL): molecular cloning, expression distribution, splice variants and DNA methylation profile," BMC Molecular Biology, vol. 8, article 18, 2007.
156. J.-B. Vannier, G. Sarek, and S. J. Boulton, "RTEL1: functions of a disease-associated helicase," Trends in Cell Biology, vol. 24, no. 7, pp. 416-425, 2014.
157. Z. Deng, G. Glousker, A. Molczan et al., "Inheritedmutations in the helicase RTEL1 cause telomere dysfunction and hoyeraalhreidarsson syndrome," Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 36, pp. E3408-E3416, 2013.
158. K. Buiting, C. Körner, B. Ulrich, E. Wahle, and B. Horsthemke, "The human gene for the poly(A)-specific ribonuclease (PARN) maps to 16p13 and has a truncated copy in the Prader-Willi/Angelman syndrome region on 15q11→q13," Cytogenetics and Cell Genetics, vol. 87, no. 1-2, pp. 125-131, 1999.
159. H. Tummala, A. Walne, L. Collopy et al., "Poly(A)-specific ribonuclease deficiency impacts telomere biology and causes dyskeratosis congenita," The Journal of Clinical Investigation, vol. 125, no. 5, pp. 2151-2160, 2015.
160. Y. A. Bochkov, K. M. Hanson, S. Keles, R. A. Brockman-Schneider, N. N. Jarjour, and J. E. Gern, "Rhinovirus-induced modulation of gene expression in bronchial epithelial cells from subjects with asthma," Mucosal Immunology, vol. 3, no. 1, pp. 69-80, 2010.
161. L.-H. Pan, H. Ohtani, K. Yamauchi, and H. Nagura, "Coexpression of TNFα and IL-1β in human acute pulmonary fibrotic diseases: an immunohistochemical analysis," Pathology International, vol. 46, no. 2, pp. 91-99, 1996.
162. L. Liu, A.A. Roberts, and T. Ganz, "ByIL-1 signaling, monocytederived cells dramatically enhance the epidermal antimicrobial response to lipopolysaccharide," The Journal of Immunology, vol. 170, no. 1, pp. 575-580, 2003.
163. S. Perrier, F. Darakhshan, and E. Hajduch, "IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?" FEBS Letters, vol. 580, no. 27, pp. 6289-6294, 2006.
164. R. Wei, C. Li, M. Zhang et al., "Association between MUC5B and TERT polymorphisms and different interstitial lung disease phenotypes," Translational Research, vol. 163, no. 5, pp. 494-502, 2014.
165. D. J. Thornton, K. Rousseau, and M. A. McGuckin, "Structure and function of the polymeric mucins in airways mucus," Annual Review of Physiology, vol. 70, pp. 459-486, 2008.
166. R. Sepper, K. Prikk, M. Metsis et al., "Mucin5B expression by lung alveolar macrophages is increased in long-term smokers," Journal of Leukocyte Biology, vol. 92, no. 2, pp. 319-324, 2012.
167. R. Borie, B. Crestani, P. Dieude et al., "The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the european caucasian population," PLoS ONE, vol. 8, no. 8, Article ID e70621, 2013.
168. J. A. Kropski, J. M. Pritchett, D. F. Zoz et al., "Extensive phenotyping of individuals at risk for familial interstitial pneumonia reveals clues to the pathogenesis of interstitial lung disease," American Journal of Respiratory and Critical Care Medicine, vol. 191, no. 4, pp. 417-426, 2015.
169. M. A. Coghlan, A. Shifren, H. J. Huang et al., "Sequencing of idiopathic pulmonary fibrosis-related genes reveals independent single gene associations," BMJ Open Respiratory Research, vol. 1, no. 1, Article ID e000057, 2014.
170. S. Lührig, I. Siamishi, M. Tesmer-Wolf, U. Zechner, W. Engel, and J. Nolte, "Lrrc34, a novel nucleolar protein, interacts with Npm1 and Ncl and has an impact on pluripotent stem cells," Stem Cells and Development, vol. 23, no. 23, pp. 2862-2874, 2014.